title: What is the best surveillance for hepatocellular carcinoma in chronic carriers of hepatitis B?
abstract: Screening patients with chronic hepatitis B infection (HBsAg+) for hepatocellular carcinoma by alpha-fetoprotein (AFP) or by AFP plus ultrasound (AFP/US) detects hepatocellular carcinoma tumors at earlier stages and increases resection rates (strength of recommendation [SOR]: B, based on a systematic review of fair-quality randomized controlled trials). It is unclear whether screening with AFP or AFP/US improves disease-specific or all-cause mortality (SOR: B).
authors.affiliation: Oregon Health and Science University, Portland, OR, USA.
authors.forename: J Bruin
authors.initials: JB
authors.lastname: Rugge
authors.forename: Jennifer
authors.initials: J
authors.lastname: Lochner
authors.forename: Dolores
authors.initials: D
authors.lastname: Judkins
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000209:etiology; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D006515:Hepatitis B virus / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000821:virology; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000209:etiology; D008403:Mass Screening / Q000379:methods*; D012307:Risk Factors
chemical_list: D006514:Hepatitis B Surface Antigens